Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa
May 19, 2023 13:57 ET
|
Krystal Biotech, Inc.
Dystrophic Epidermolysis Bullosa (DEB) is a serious rare genetic disease that affects the skin and mucosal tissues and is caused by one or more mutations in the COL7A1 gene, resulting in lack of...
Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights
May 08, 2023 08:23 ET
|
Krystal Biotech, Inc.
PDUFA date of May 19, 2023Presented clinical data at ARVO on topical application of B-VEC to the eye to treat ocular complications in a patient with recessive dystrophic epidermolysis bullosa under...
Krystal Biotech Announces Clinical Data on Topical Application of B-VEC to the Eye to Treat Ocular Complications in a Patient with Dystrophic Epidermolysis Bullosa Under a Compassionate Use Program
April 24, 2023 07:00 ET
|
Krystal Biotech, Inc.
Data presented at Association for Research in Vision and Ophthalmology Annual Meeting on April 23, 2023Topical application of B-VEC to the eye was well tolerated and patient showed significant...
Krystal Biotech to Present at Association for Research in Vision and Ophthalmology Annual Meeting
April 13, 2023 07:00 ET
|
Krystal Biotech, Inc.
Clinical data on the compassionate use of B-VEC to treat a RDEB patient, with recurrent cicatrizing conjunctivitis that leads to conjunctival scarring, at the Bascom Palmer Eye Institute PITTSBURGH,...
Krystal Biotech Appoints Catherine Mazzacco to Board of Directors
March 06, 2023 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, March 06, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients...
Krystal Biotech to Present at the 43rd Annual TD Cowen Health Care Conference
March 02, 2023 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, March 02, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients...
Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
February 27, 2023 07:00 ET
|
Krystal Biotech, Inc.
• B-VEC PDUFA date May 19, 2023 • Data from the pivotal Phase 3 (GEM-3) trial of B-VEC for dystrophic epidermolysis bullosa published in the New England Journal of Medicine • Four pipeline clinical...
Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis
January 18, 2023 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients...
Krystal Biotech Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis Bullosa
January 09, 2023 08:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that on January 5, 2023, the U.S. Food and Drug Administration (FDA) notified the...
New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa
December 14, 2022 17:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients...